secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001711279-24-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track
--------------------------------------------------------------------------------

- VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.
- Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.
- Cash and investments $628.9M at June 30, 2024; strong balance sheet.
- On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).
- Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/0001711279-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/krys-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer